Viberzi (eluxadoline) does interact with opioid receptors, but it is not a traditional opioid like morphine, oxycodone, or other pain medications. It is classified as a mixed opioid receptor agonist that works primarily in the gut, not the brain, and is approved specifically for treating irritable bowel syndrome with diarrhea (IBS-D). The DEA classifies it as a Schedule IV controlled substance, placing it in the same category as drugs with low abuse potential.
How Viberzi Interacts With Opioid Receptors
Your gut is lined with opioid receptors that help regulate how fast food moves through your intestines, how much fluid your intestines secrete, and how much pain you feel in your abdomen. Viberzi targets these receptors directly. It activates one type (mu receptors), which slows intestinal movement and reduces diarrhea. At the same time, it blocks another type (delta receptors), which helps prevent the severe constipation that traditional opioids cause. It also has some activity at a third type (kappa receptors), though the exact role of that interaction isn’t fully understood.
This combination is what makes Viberzi fundamentally different from opioid pain medications. Drugs like oxycodone or hydrocodone activate mu receptors throughout the body, including in the brain, producing pain relief, euphoria, and a high risk of dependence. Viberzi’s mixed receptor activity and its focus on the gut give it a very different profile.
Does Viberzi Affect the Brain?
Viberzi has low oral bioavailability, meaning very little of the drug reaches general circulation after you swallow it. Most of its activity stays local, in the gastrointestinal tract. It does technically cross the blood-brain barrier, but FDA pharmacodynamic studies found no meaningful central nervous system effects. Researchers measured pupil size changes, mood scales, and subjective drug-effect questionnaires at various doses and found no dose-related trends, confirming that Viberzi does not produce the brain-level effects associated with traditional opioids.
In practical terms, this means Viberzi does not cause the “high” or mental clouding that opioid pain medications produce.
Abuse Potential and Dependence Risk
Clinical trials specifically evaluated whether patients showed signs of opioid-like abuse or withdrawal. Across Phase 2 and Phase 3 studies, adverse events potentially related to abuse (primarily anxiety and drowsiness) occurred in less than 2% of patients in each group and did not differ significantly between people taking Viberzi and those taking a placebo. Withdrawal scores, measured on a standardized scale, were essentially identical between the Viberzi groups and the placebo group.
Based on this data, the DEA placed Viberzi in Schedule IV when it was approved. The agency determined that its overall abuse potential was comparable to other Schedule IV substances like pentazocine and butorphanol, and that misuse could lead to limited psychological dependence at most. For context, Schedule IV is two tiers below Schedule II, where drugs like oxycodone and fentanyl sit.
Standard Dosing
Viberzi is taken as a tablet twice daily with food. The standard dose is 100 mg twice a day, though some patients take 75 mg twice a day based on their individual response or tolerability.
Serious Safety Concerns
Even though Viberzi carries far less risk than traditional opioids in terms of addiction, it does have one notable safety issue: pancreatitis, particularly in people who have had their gallbladder removed.
Viberzi’s activation of mu opioid receptors can increase the tone of the sphincter of Oddi, a small muscle valve that controls the flow of digestive fluids from the pancreas and liver into the small intestine. Normally, when that valve tightens, bile gets diverted into the gallbladder as a pressure release. If you no longer have a gallbladder, that backup reservoir is gone. Pressure builds in the pancreatic duct system, which can trigger spasms or pancreatitis.
This risk was significant enough that in April 2017, the FDA updated Viberzi’s label to contraindicate its use entirely in patients without a gallbladder. If you’ve had a cholecystectomy, Viberzi is not an option.
Pancreatitis can also occur in patients who do have a gallbladder, though at lower rates. Heavy alcohol use increases the risk. Other contraindications include a history of bile duct obstruction, pancreatic disease, or severe liver problems.
How It Compares to Opioid Pain Medications
The confusion around whether Viberzi is “an opioid” comes from the fact that it interacts with the same receptor family. But opioid receptors exist throughout the body, and a drug that activates them in the gut wall behaves very differently from one that floods the brain. Traditional opioid pain medications cause constipation as a side effect precisely because they hit those same gut receptors, but their primary target is the brain. Viberzi flips that relationship: the gut effect is the whole point, and the brain effect is negligible.
You will not experience euphoria, sedation, or respiratory depression from Viberzi at prescribed doses. It does not carry the addiction warnings that apply to opioid analgesics, and the recent FDA labeling changes requiring stronger safety language on opioid pain medicines do not apply to it. That said, because it is a controlled substance, you will need a prescription each time, and pharmacies track it accordingly.